T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

Amplification of c-erbB2 has been reported in over 30% of uterine serous carcinoma (USC) and found to confer poor survival because of high proliferation and increased resistance to therapy. In this study, we evaluated for the first time Trastuzumab emtansine (T-DM1), a novel antibody–drug conjugate,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: English, Diana P, Bellone, Stefania, Schwab, Carlton L, Bortolomai, Ileana, Bonazzoli, Elena, Cocco, Emiliano, Buza, Natalia, Hui, Pei, Lopez, Salvatore, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Rutherford, Thomas J, Santin, Alessandro D
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2014
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4302675/
https://ncbi.nlm.nih.gov/pubmed/24890382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.274
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars